RS20050831A - Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni - Google Patents

Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni

Info

Publication number
RS20050831A
RS20050831A YUP-2005/0831A YUP20050831A RS20050831A RS 20050831 A RS20050831 A RS 20050831A YU P20050831 A YUP20050831 A YU P20050831A RS 20050831 A RS20050831 A RS 20050831A
Authority
RS
Serbia
Prior art keywords
vegfr
anthranylamide
pyridones
inhibit
medicaments
Prior art date
Application number
YUP-2005/0831A
Other languages
English (en)
Serbian (sr)
Inventor
Andreas Huth
Karl-Heinz Thierauch
Andreas Menrad
Martin Haberey
Rolf Bohlmann
Martin Krueger
Ludwig Zorn
Stuart Ince
Stumpp Holger Hess
Original Assignee
Schering Aktiengesellschaft,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft, filed Critical Schering Aktiengesellschaft,
Publication of RS20050831A publication Critical patent/RS20050831A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
YUP-2005/0831A 2003-06-13 2004-06-09 Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni RS20050831A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10327719A DE10327719A1 (de) 2003-06-13 2003-06-13 VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
PCT/EP2004/006236 WO2004111005A1 (de) 2003-06-13 2004-06-09 Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyridone

Publications (1)

Publication Number Publication Date
RS20050831A true RS20050831A (sr) 2008-04-04

Family

ID=33520741

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0831A RS20050831A (sr) 2003-06-13 2004-06-09 Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni

Country Status (18)

Country Link
EP (1) EP1633713A1 (de)
JP (1) JP2006527228A (de)
KR (1) KR20060021887A (de)
CN (1) CN1805936A (de)
AU (1) AU2004247377A1 (de)
BR (1) BRPI0411360A (de)
CA (1) CA2526041A1 (de)
CR (1) CR8127A (de)
DE (1) DE10327719A1 (de)
EA (1) EA200501885A1 (de)
EC (1) ECSP066280A (de)
IL (1) IL171898A0 (de)
MX (1) MXPA05013586A (de)
NO (1) NO20060196L (de)
RS (1) RS20050831A (de)
UA (1) UA81323C2 (de)
WO (1) WO2004111005A1 (de)
ZA (1) ZA200600291B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060071812A (ko) * 2004-12-22 2006-06-27 주식회사 엘지생명과학 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 아민유도체
JP6069356B2 (ja) * 2012-01-05 2017-02-01 クラノテク・アクチボラグ 線維症又は線維症関連疾患の治療に使用するための、抗血管新生性のインテグリンα５β１阻害剤であるキノリン化合物
CN106496107A (zh) * 2016-08-31 2017-03-15 浙江永宁药业股份有限公司 Vegfr‑2抑制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US20040254185A1 (en) * 2001-05-08 2004-12-16 Alexander Ernst Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
GB0126902D0 (en) * 2001-11-08 2002-01-02 Novartis Ag Organic compounds
DE10228090A1 (de) * 2002-06-19 2004-01-15 Schering Ag Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
AU2004247377A1 (en) 2004-12-23
WO2004111005A1 (de) 2004-12-23
MXPA05013586A (es) 2006-03-09
UA81323C2 (en) 2007-12-25
DE10327719A1 (de) 2005-01-20
KR20060021887A (ko) 2006-03-08
JP2006527228A (ja) 2006-11-30
CN1805936A (zh) 2006-07-19
BRPI0411360A (pt) 2006-07-25
ECSP066280A (es) 2006-07-28
CR8127A (es) 2006-05-29
CA2526041A1 (en) 2004-12-23
ZA200600291B (en) 2007-03-28
IL171898A0 (en) 2006-04-10
NO20060196L (no) 2006-01-12
EP1633713A1 (de) 2006-03-15
EA200501885A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
HK1096392A1 (en) Substituted heterocycles
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
TW200510416A (en) P38 inhibitors and methods of use thereof
GB0222495D0 (en) Compounds
TW200637522A (en) Skin treatment articles and methods
WO2001085715A3 (de) Aza- und polyazanthranylamide und deren verwendung als arzneimittel
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DE60218445D1 (de) Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
TW200611695A (en) Pyrrolopyridine derivatives
YU31801A (sh) Amidi antranilne kiseline i njihova upotreba kao leka
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
TW200621714A (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2005070450A8 (de) Verwendung von niedrig dosiertem erythropoietin zur behandlung von akuter oder chronischer niereninsuffizienz und zur behandlung von wunden
HK1130011A1 (en) Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative
ZA201006782B (en) Novel p2x7r antagonists and thier use
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
TW200726763A (en) Novel compound
EE200300366A (et) Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
SE0300457D0 (sv) Novel compounds